title: [Use of OKT-3 in treatment of rejection following kidney transplantation].
abstract: Application of OKT-3 as rescue therapy in steroid-resistant rejection was effective in 7 out of 9 patients early after cadaveric kidney transplantation. Under attention of instructions for use of OKT-3 the adverse first-dose reactions are rare. The problem of OKT-3 therapy is early use and its reuse.
authors.affiliation: Urologische Klinik und Poliklinik, Humboldt-Universität Berlin.
authors.forename: C
authors.initials: C
authors.lastname: Hansen
authors.forename: P
authors.initials: P
authors.lastname: Müller
authors.forename: F
authors.initials: F
authors.lastname: Seibt
authors.forename: H
authors.initials: H
authors.lastname: Oesterwitz
authors.forename: G
authors.initials: G
authors.lastname: May
authors.forename: V
authors.initials: V
authors.lastname: Strobelt
authors.forename: J
authors.initials: J
authors.lastname: Kaden
authors.forename: G
authors.initials: G
authors.lastname: Ditscherlein
authors.forename: D
authors.initials: D
authors.lastname: Scholz
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3; D011183:Postoperative Complications / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003404:Creatinine
vernacular_title: Einsatz von OKT-3 bei der Rejektionsbehandlung nach Nierentransplantation.